drugset / Trial / NCT00422084

Pyronaridine Artesunate (3:1) Versus Coartem® in P Falciparum Malaria Patients

NCT00422084

RandomizedParallel-groupTriple-blindTreatment

Summary

The primary objective of this phase III study is to compare the efficacy and safety of the fixed combination of pyronaridine artesunate (Pyramax®, PA) with that of Coartem® (artemether lumefantrine, AL) in children and adults with uncomplicated P falciparum malaria in Africa and South East Asia.

Timeline

Start
2007-01
Primary completion
2008-04
Completion
2008-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Artemether-lumefantrine Unknown 20 mg Oral
Comparator Artemether-lumefantrine Unknown 120 mg Oral
Subject pyronaridine-artesunate Other / unclassified 60 mg Oral
Subject pyronaridine-artesunate Other / unclassified 180 mg Oral

Indications